Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals

Archives of General Psychiatry

Volumn 57, Issue 10, 2000, Pages 987-994

  Essock, Susan M ^a,b,c   Frisman, Linda K ^b,c   Covell, Nancy H ^b,c   Hargreaves, William A ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Forensic Services for the Connecticut Department of Mental Health and Addiction Services   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0033804861     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.57.10.987     Document Type: Article

References (41)

1. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia
2. Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial
3. Clozapine eligibility among state hospital patients
4. Clozapine for the treatment resistant schizophrenic: A double-blind comparison with chlorpromazine
5. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia
6. Pharmacoeconomic evaluation of treatments for refractory schizophrenia: Clozapine-related studies
7. Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia
8. Hospitalization rates among clozapine-treated patients: A prospective cost-benefit analysis
9. Cost-effectiveness of clozapine therapy for severe psychosis
10. Initiating clozapine treatment in the outpatient clinic: Service utilization and cost trends
11. Clozapine for refractory schizophrenia: The Illinois experience
12. A two-year clinical and economic follow-up of patients on clozapine
13. New vs. old antipsychotics: The Texas experience
14. Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system
15. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients
16. Health status and health care costs for publicly funded patients with schizophrenia started on clozapine
17. Cost-effectiveness of clozapine in neuroleptic-resistant schizophrenia
18. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia
19. Clozapine's cost-effectiveness
20. Letter to the editor re Revicki et al (1990)
21. Letter to the editor re Revicki et al (1990)
22. Reply to Frank and Goldman comments on Revicki et al (1990)
23. Clozapine's cost-effectiveness
24. Clozapine's cost-effectiveness
25. The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling
26. A quality of life interview for the chronically mentally ill
27. The effects of psychiatric symptoms on quality of life assessments among the chronic mentally ill
28. Evaluation of drug-related movement disorders in the aged
29. Reducing the use of physical restraints in nursing homes: Will it increase costs?
30. How transfer payments are treated in cost-effectiveness and cost-benefit analyses
31. The resampling method of statistical analysis
32. Estimating confidence intervals for cost-effectiveness ratios: An example from a randomized trial
33. Cost-effectiveness of treatments for major depression in primary care practice
34. Confidence intervals or surfaces? uncertainty on the cost-effectiveness plane
35. The CE plane: A graphic representation of cost-effectiveness
36. Are antipsychotic drugs interchangeable?
37. Clinical trials in psychiatry: Should protocol deviation censor patient data?
38. Cost-effectiveness of clozapine in patients with high and low levels of hospital use
39. Cost-effectiveness of assertive community treatment teams